Allergy Therapeutics plc Stock price

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:20 2024-03-28 pm EDT 5-day change 1st Jan Change
3 GBX 0.00% Intraday chart for Allergy Therapeutics plc +10.29% +20.00%
Sales 2022 72.77M 91.85M Sales 2023 59.59M 75.21M Capitalization 7.13M 9M
Net income 2022 -13M -16.41M Net income 2023 -43M -54.27M EV / Sales 2022 1.7 x
Net cash position 2022 9.99M 12.6M Net Debt 2023 21.14M 26.69M EV / Sales 2023 0.47 x
P/E ratio 2022
-9.69 x
P/E ratio 2023
-0.16 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 6.79%
More Fundamentals * Assessed data
Dynamic Chart
1 week+9.09%
Current month+25.00%
1 month+22.45%
3 months+20.00%
6 months+87.50%
Current year+20.00%
More quotes
1 week
2.50
Extreme 2.5
3.20
1 month
2.20
Extreme 2.2
3.20
Current year
1.80
Extreme 1.8
3.20
1 year
0.80
Extreme 0.8
3.90
3 years
0.80
Extreme 0.8
40.50
5 years
0.80
Extreme 0.8
40.50
10 years
0.80
Extreme 0.8
40.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 09-06-30
Director of Finance/CFO - 22-03-31
Chief Tech/Sci/R&D Officer - 03-12-31
Members of the board TitleAgeSince
Director/Board Member 67 17-06-05
Chairman 73 10-09-30
Director/Board Member 62 19-06-18
More insiders
Date Price Change Volume
24-03-28 3 0.00% 118 195
24-03-27 3 +11.11% 1,499,989
24-03-26 2.7 -1.82% 1,172,293
24-03-25 2.75 0.00% 340,728
24-03-22 2.75 0.00% 219

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
  1. Stock
  2. Equities
  3. Stock Allergy Therapeutics plc - London S.E.